Six consecutive years! Medicilon once again tops the '2023 China CXO Enterprise Top 20 List'

On June 25^th, the "Resilience and Innovation: 2024 Mithink Summit" hosted by Menet, a subsidiary of the Southern Institute of Medical Economics under the National Medical Products Administration, released the 2023 China Pharmaceutical Industry Top 100 Rankings lists. Medicilon, with its outstanding R&D capabilities and continuous spirit of innovation, has once again topped the 2023 China CXO (including CDMO) Enterprise Top 20 List. This is the sixth consecutive year that Medicilon has received this honor.

Medicilon's sixth consecutive win of this honor not only represents the industry's authoritative recognition of its comprehensive biopharmaceutical preclinical R&D service platform, but also affirms its contributions to the pharmaceutical research and development field.

About the China's Top 100 Pharmaceutical Industry List Series

The "China's Top 100 Pharmaceutical Industry List Series" as an authoritative industry list, initiated and hosted by Menet.com.cn, aims to set benchmarks for china pharmaceutical enterprises to enhance comprehensive strength, expand brand influence, showcase outstanding achievements in the pharmaceutical industry, and guide stable, rapid, and sustainable development in the healthcare industry. Menet Research Institute, leveraging its exclusively developed and operated database covering three major terminals and six market segments, conducted a rigorous and scientific selection process based on two crucial dimensions for pharmaceutical industry enterprises: innovation driving force and professional promotion capability. This process ultimately determined the China's Top 100 Pharmaceutical Industry List Series.

With the rapid development of pharmaceutical technology, emerging fields such as bispecific/multispecific antibodies, ADCs, PROTACs, mRNA vaccines, small nucleic acids, and cellular and immune therapies are gradually becoming the focus of industry attention. Medicilon actively plans forward, establishing a series of efficient and cutting-edge technology service platforms, continuously driving technological innovation and iteration, and leading industry development trends. As of the end of April 2024, Medicilon has provided drug development services to over 2,000 global clients. They have been involved in the research and development of 480 new drug and generic drug projects, with IND approvals obtained from regulatory authorities such as China NMPA, the US FDA, the EU EMEA, and Australia TGA, allowing entry into clinical trials.

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客